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Abstract
Background: Recent medical guidelines emphasize the importance of actively treating overweight and obesity
with diet and lifestyle intervention to achieve ≥5 % weight loss in a 6-month period. Commercial programs offer
one approach provided there is evidence of their efficacy and safety. This study was conducted to evaluate the
effectiveness of the Medifast® 4 & 2 & 1 Plan™ on weight loss, body composition and cardiometabolic risk factors in
overweight and obese adults.
Methods: A systematic retrospective chart review of 310 overweight and obese clients following the Medifast 4 & 2
& 1 Plan at one of 21 Medifast Weight Control Centers® was conducted. Data were recorded electronically and key
data points were independently verified. The primary endpoint was change from baseline body weight at 12 weeks.
Within group paired t-tests were used to examine changes from baseline in a completers population. Differences
between gender and age subgroups were examined using bivariate t-tests and mixed model regression analyses.
Results: For the primary endpoint at 12 weeks, body weight among completers (n = 185) was reduced by a mean of
10.9 ± 5.6 kg (-10.1 %, p < 0.0001), and at 24 weeks (n = 81) mean weight was reduced by 16.0 ± 7.9 kg (-14.3 %). At 12
and 24 weeks, 85 % and 96 % of those remaining on the plan, respectively, had lost ≥5 % of their baseline body
weight. Lean mass was preserved to within 5 % of baseline throughout the 24 weeks, and fat mass represented ≥80 %
of the body weight lost from 12 weeks onward. Men, women, seniors (≥65 years), and non-seniors (<65 years) all had
significant weight reductions with preservation of lean mass. Significant improvements in blood pressure, pulse
and waist-to-hip ratio were observed. Mean weight regain among the subset who entered a formal maintenance
phase was <2 % during an average follow-up of 34 weeks. The meal plan was well tolerated, and program
adherence was >85 %.
Conclusions: The 4 & 2 & 1 Plan used at Medifast Weight Control Centers was effective for weight loss,
preservation of lean mass and improvement in cardiometabolic risk factors. The plan was generally well tolerated
in a broad population of overweight and obese adults. #NCT02150837.
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Introduction
Overweight and obesity are linked to a multitude of ser-
ious comorbidities, and obesity carries an additional risk
of greater all-cause and cardiovascular disease mortality
[1]. Currently, 69 % of adults in the United States are
overweight and 35 % are obese [2]. The health conse-
quences of overweight and obesity have been described
as “the most burdensome public health issue facing the
Nation”, and both prevention and intervention are rec-
ommended [3]. While recent trends seem to indicate
that overall increases in the prevalence of obesity may
be leveling off, the rates of obesity in men significantly
increased between 1998 and 2008, and the 2010 age-
adjusted rates indicate women aged 60 and older have
the highest rates of obesity at 42.3 % [4, 5]. Unfortu-
nately, there is a paucity of research in both men and
older adults as most existing weight loss intervention
studies have under-represented or excluded these popu-
lations [6, 7].
For overweight or obese individuals, even a relatively
small amount of weight loss can reduce the risk of devel-
oping related co-morbidities, such as cardiovascular dis-
ease, type 2 diabetes and some forms of cancers [1, 8–11].
Understanding obesity as a complex, chronic disease is es-
sential for providing effective interventions and “obli-
gate[s] clinicians to go beyond mere recommendations to
eat less and move more” [12, 13]. Recent guidelines issued
by the American Heart Association, the American College
of Cardiology and The Obesity Society for the manage-
ment of overweight and obesity in adults recommend par-
ticipation in a comprehensive lifestyle program, which
includes a reduced calorie diet along with exercise and be-
havior change components, as the cornerstone of all treat-
ment options for overweight and obese individuals, with
the goal of achieving clinically meaningful weight loss of
at least 5–10 % in a 6-month period [1]. Commercial pro-
grams that provide a comprehensive lifestyle intervention
are also supported as an option for weight loss within
these guidelines, provided they are backed by evidence of
their safety and efficacy. Additionally, evidence also sup-
ports the use of meal replacements as part of a structured
approach to obesity treatment, as meal replacements have
been shown to be a safe and effective tool for limiting cal-
orie intake and promoting weight loss and weight main-
tenance among overweight and obese individuals [14, 15].
The Medifast® Program is a commercial program that
features a combination of Medifast Meal Replacements,
conventional food choices, and customizable levels of
support for weight loss and weight maintenance. At
Medifast Weight Control Centers® (MWCC), the Medifast
meal plans are combined with individualized one-on-one
weekly counseling to create a comprehensive lifestyle pro-
gram. One of the meal plans available for weight loss is
the Medifast 4 & 2 & 1 Plan™, an alternative, slightly
higher calorie weight loss plan than the most frequently
used Medifast 5 & 1 Plan®. The Medifast 4 & 2 & 1 Plan is
often recommended for men and seniors (≥65 years), or
based on specific individual behaviors or food preferences
(e.g., individual engages in high levels of physical activity
or wants to include fruit, dairy or whole grains daily). Both
the 5 & 1 and the 4 & 2 & 1 Plans are designed to provide
adequate protein to promote retention of lean mass dur-
ing weight loss. Previous studies have shown the 5 & 1
Plan to be safe and effective for weight loss in overweight
and obese individuals [16–18]. The purpose of this study
was to evaluate the effectiveness of the Medifast 4 & 2 & 1
Plan for weight loss across 24 weeks (primary endpoint at
12 weeks) in overweight and obese adults who used this
plan at MWCCs. Secondary objectives included assessing
effects of this plan on body composition and cardiometa-
bolic risk factors. Post hoc evaluations of body weight by
gender and age category (<65 and ≥ 65 years) were also
conducted.
Methods
This study was a systematic retrospective chart review of
MWCC clients who started the Medifast 4 & 2 & 1 Plan
for weight loss on or after January 1, 2012 and com-
pleted the active Weight Loss phase of their program by
March 31, 2014. Twenty-one MWCCs were chosen for
this study based on (a) their close proximity to Medifast
corporate headquarters (all MWCCs in Maryland), or (b)
because they were among the centers with the largest base
of clients following the 4 & 2 & 1 Plan – these MWCCs
were located in Texas, Florida, and Pennsylvania. The
MWCC point-of-sale system was used to identify charts
of clients who purchased the 4 & 2 & 1 Plan. Once identi-
fied, charts were pre-screened at each MWCC for the
presence of a signed personal health information (PHI)
consent form (which included permission to use their data
for research purposes), and then shipped to corporate
headquarters for formal screening and data abstraction.
Charts from clients who met the following study
selection criteria were included: male or female over-
weight or obese adult (age ≥ 18 years, BMI ≥ 25 kg/m2),
signed a PHI form, started the 4 & 2 & 1 Plan after
January 1, 2012, followed the 4 & 2 & 1 Plan for at least
2 weeks, and not concurrently using any other weight
loss program or pharmacotherapy for weight loss. The
study was approved by an independent institutional re-
view board (Western Institutional Review Board, Puyallup,
WA) which concluded that the study met the require-
ments for a waiver from the informed consent process per
45 CFR 66.116(d). This study adhered to current meth-
odological standards for retrospective chart reviews [19]
and was registered in the ClinicalTrials.gov database
(#NCT02150837).
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The weight management program offered at the
MWCC consists of weekly one-on-one in-person sessions
with MWCC counselors who utilize motivational inter-
viewing and a series of personalized behavior change strat-
egies designed to develop behaviors that promote
long-term weight management through a healthy life-
style. MWCC counselors are trained using a combin-
ation of on-the-job and corporate-based training to
ensure thorough knowledge of the Medifast products
and programs and an understanding of the behavior
change strategies used at MWCC. A client’s weight
loss goals are determined jointly by the counselor and
client, which in turn determines the prescribed length
of the client’s active Weight Loss phase and overall
weight management program. Programs generally in-
clude active Weight Loss, Transition, and Maintenance
phases. The meal plan chosen for weight loss is also deter-
mined jointly based on a number of factors including the
client’s personal preferences, lifestyle, exercise habits and
medical history.
The 4 & 2 & 1 Plan is a calorie- and portion-controlled
meal plan designed to stimulate gradual, steady weight
loss and provides 1,100-1,300 calories daily. It consists of
4 Medifast Meal Replacements, 2 self-prepared “lean and
green meals” (each including 5–7 oz of lean protein, 3
servings (~1½ cups) of non-starchy vegetables, and up to
2 healthy fat servings), and 1 healthy snack (fruit, dairy or
whole grains). Medifast Meal Replacements, of which
there are over 70 to choose from, each contain 90–110
calories, 11–15 g protein (primarily from soy and/or
dairy), 8–15 g carbohydrates, and 0–3.5 g fat; they each
share a similar nutritional profile and can be used inter-
changeably during the Weight Loss phase and with any of
the Medifast weight loss meal plans. Following the Weight
Loss phase, some MWCCs may include a Transition
phase, during which calorie intake and conventional food
choices are gradually increased. All individuals who meet
their weight loss goal or who have completed their pre-
scribed weight loss weeks then have the option to enter
the Maintenance phase. The Medifast Maintenance Plan
is based on a client’s total energy expenditure (TEE) and
generally includes 3 Medifast Meal Replacements and 3
self-prepared meals (consisting of conventional food
choices with serving sizes based on the Exchange List for
Weight Management; the number of servings is individu-
alized based on TEE).
Data were recorded in client charts at MWCCs by
counselors. Counselors were trained to use consistent
procedures when obtaining weights and anthropometric
measurements. Weight was measured to the nearest 0.1 lb
using a high-quality digital scale. Body composition was
assessed without shoes and in light indoor clothing by dir-
ect, segmental, multi-frequency bioelectrical impedance
analysis using either an InBody 230® or InBody 370® body
composition analyzer (InBody Co., Cerritos, CA, USA);
measurements of fat mass, percent body fat and fat free
mass obtained using the InBody analyzer are highly corre-
lated (r ≥ 0.97) to measurements made by dual energy X-
ray absorptiometry (DXA) [20]. Blood pressure and pulse
were measured using digital arm blood pressure monitors.
Adherence was assessed based on clients’ visit attend-
ance and self-reported meal replacement
consumption.
Weight, pulse, blood pressure, and adherence-related
information were abstracted at baseline and weekly
throughout the client’s Weight Loss phase through
24 weeks plus at the Final Visit. The Final Visit was de-
fined as the client’s last visit to the MWCC during active
weight loss while following the 4 & 2 & 1 Plan; the time
of the Final Visit varied by individual client. Anthropo-
metrics and body composition information, which were
measured approximately every 4 weeks at the MWCCs,
were also collected. When available, body weight data
and the corresponding dates were abstracted at the
beginning and end of any other MWCC meal plans or
program phases that followed a client’s use of the 4 & 2
& 1 Plan.
Notations of adverse signs, symptoms or incidents that
occurred while a client was on the 4 & 2 & 1 Plan were
abstracted verbatim from the chart notes, regardless of
whether or not the incident appeared to be related to
the intervention. This information was reviewed and cat-
egorized by a registered nurse, and simple frequencies
were tabulated.
Chart data were abstracted by trained study personnel
directly into electronic case report forms developed
using IBM SPSS Data Collection Author and Interviewer
Version 7, according to conventions developed for this
study. A two-user, independent (double-data) data entry
procedure was used for verification of all key data
points.
Power calculations and statistical analysis
The primary outcome in this study was change from
baseline body weight at 12 weeks. Sample size was deter-
mined using a 10 % standard deviation, 0.05 significance
level and with the assumption that up to 50 % of the
charts would not have weight outcome data at the 12-
week time point (e.g., clients completed their program,
dropped out, switched to another meal plan before
12 weeks, or had missing data for this time point). From
these assumptions, a minimum of 64 charts was re-
quired to attain 80 % power in order to detect clinically
meaningful weight loss of 5 % from baseline using a
paired t-test for a within-group comparison.
Data were analyzed according to a pre-defined statis-
tical analysis plan. Normality testing was performed.
Wilcoxon signed rank tests (i.e., paired t-tests for
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repeated measures nonparametric data) were used to
compare within group changes in weight at 12 weeks
compared to baseline for the primary analysis and at
other predetermined time points (1, 2, 4, 8, 16, 20
and 24 weeks). When appropriate, results from para-
metric and non-parametric tests were performed to
ensure they provided similar findings. Because of the
retrospective nature of the study, predefined windows
that used data closest to the specified time point were
established to optimize the sample without bias: data
were included if available within ±3 days for the 1
and 2 week time points, ±7 days for the 4 week time
point, and within ±10 days for the remaining time
points. For the primary analysis, a completers analysis
was used; this analysis included each chart that had
data for the given outcome and time point, irrespect-
ive of whether the individual completed his/her entire
program. Similar analyses were conducted on second-
ary outcomes. An intention-to-treat (ITT) last obser-
vation carried forward (LOCF) analysis, pre-specified
in the protocol, was also performed for the primary
outcome for comparison. If missing, imputed data were
carried through from the last measured observation to
each client’s last prescribed week of weight loss. Add-
itionally, in order to maximize the use of all data, in-
cluding those with missing data, a pre-specified mixed
model regression approach was used on the primary
outcome, weight, with time as the independent variable
and baseline weight as a covariate. The proportions of
individuals achieving ≥5 % and ≥10 % weight loss from
baseline were calculated. Post hoc subgroup analyses by
gender and by senior status (<65, ≥65 years) were per-
formed on body weight and body composition. Weight
results were converted from lbs to kg and circumfer-
ence measurements were converted from inches to cm.
Program adherence was defined for meal replacements
as: ≥75 % compliance of meal replacement consump-
tion (i.e., on average 3 of the 4 assigned meal replace-
ments were reported consumed) and for attendance as
reporting to ≥75 % of their weekly visits while on the
program. Differences between groups were examined
using bivariate t-tests as well as mixed model regression
analyses. Significance was defined as p < 0.05 with no
adjustments for multiplicity. Analyses were conducted
using SPSS Version 14.0 and Stata Version 10.
Results
Chart selection and flow
Of the 478 charts received for screening, 310 met the
study entry criteria and were included in the study. Five
criteria accounted for 96 % of the charts excluded during
the screening process (Fig. 1). Sixty percent (n = 185) of
individuals who started the 4 & 2 & 1 Plan remained on
this plan and had weight data within the 12-week visit
window and were, therefore, included in the completers
analysis at the 12-week primary endpoint; 26 % (n = 81)
remained on the 4 & 2 & 1 Plan and had weight data
within the 24-week visit window and were, therefore, in-
cluded in the completers analysis at this time point.
Among the main reasons for discontinuing the 4 & 2 & 1
Plan were loss to follow-up, switching to another Medifast
meal plan, and completion of the individual’s prescribed
program length (Fig. 1). The Intention-to-Treat Last
Observation Carried Forward (ITT LOCF) analyses
(not shown in the diagram) included all charts with
baseline weight data and for which the prescribed pro-
gram length did not exceed the specified time point.
The ITT LOCF analysis at 12 weeks included 281
charts (28 charts were excluded because the pre-
scribed program length was <12 weeks, and one was
excluded for no baseline weight); the ITT analysis at
24 weeks included 157 charts (excluded were 151 be-
cause the prescribed program length was <24 weeks,
one because a prescribed program length was not spe-
cified, and one for no baseline weight).
Baseline characteristics
The group was comprised of 57.1 % females and 42.9 %
males (Table 1). The mean (±SD) BMI was 37.7 ±
6.8 kg/m2 and included a broad distribution of weight
classes including overweight, and class I, II and III
obesity. The mean age was 53.5 ± 14.7 years, and 28 %
were seniors age 65 years or older. Self-reported co-
morbid conditions were prevalent in the group, includ-
ing high blood sugar/diabetes (predominantly type 2),
high blood pressure, and arthritis.
Body weight
For the primary endpoint at 12 weeks, weight among
completers (n = 185) was reduced by a mean of 10.9 ±
5.6 kg (−10.1 %, p < 0.0001, Fig. 2). Overall, mean body
weight decreased steadily and significantly compared to
baseline through 24 weeks and at Final Visit among
completers (p < 0.0001 for all time points; Fig. 2 and
Additional file 1). The most rapid decrease occurred in
the first 2 weeks (mean ± SD: −3.7 ± 1.9 kg or −3.4 % of
baseline weight, n = 280). Among the 81 individuals with
weight data at 24 weeks, all had lost weight (−16.0 ±
7.9 kg or −14.3 % of baseline weight). In a random
effects regression model, controlling for baseline weight,
the average rates of weight loss (95 % CI) over 2, 12, and
24 weeks were −1.89 (−1.99, −1.79), −0.84 (−0.86, −0.82),
and −0.63 (−0.65, −0.61) kg per week (p < 0.0001, see Add-
itional file 2). As previously noted, Final Visit describes
the last weekly visit each client attended during active
weight loss while following the 4 & 2 & 1 Plan, and
the time to Final Visit varied by individual client.
Mean weight loss at the clients’ Final Visit on the 4 & 2 &
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1 Plan (n = 306, mean length of participation 17.4 weeks)
was -10.6 ± 8.5 kg corresponding to a 9.6 % reduction in
baseline weight. In agreement with the completers
analysis, the results of the ITT LOCF analysis also showed
steady and significant (p < 0.0001) weight reductions at
all times, with 8.9 kg (7.9 %) and 11.5 kg (9.4 %) reduc-
tions at 12 and 24 weeks, respectively (see Fig. 2 and
Additional file 3).
In the completers analysis, half (50.2 %) of the individuals
had lost at least 5 % of their baseline body weight by
4 weeks (Fig. 3). Of the clients who followed the program
for at least 12 weeks, 85 % had lost at least 5 % and half
had lost at least 10 % of their baseline body weight. By
24 weeks, nearly all (96 %) had lost at least 5 % and three
quarters had lost at least 10 % of their baseline body weight.
In an ITT LOCF analyses, approximately 70 % had
lost ≥5 % of their baseline weight by 12 and 24 weeks
(Additional file 4).
Body composition
Weight loss on the 4 & 2 & 1 Plan was accompanied by
significant reductions in body fat mass and proportion-
ate increases in lean body mass: lean body mass in-
creased from 57 % of body weight at baseline to 62 % at
12 weeks and to 64 % at 24 weeks, whereas body fat
mass decreased from 43 % of body weight at baseline to
38 % at 12 weeks and to 35 % at 24 weeks. Absolute lean
mass decreased during the first 4 weeks on the plan
(−2.0 ± 2.1 kg, p < 0.0001) and was largely conserved
thereafter (3.1 ± 2.9 kg reduction at 24 weeks, p < 0.0001,
representing <5 % of baseline lean mass) compared to
body fat mass which declined continuously throughout
the study period (Fig. 4). Fat mass was ultimately re-
duced by 14.5 ± 7.2 kg, representing >30 % reduction
from baseline at 24 weeks. Fat mass represented ap-
proximately 67, 80 and 83 % of the total body mass lost
at 4, 12 and 24 weeks, respectively.
Fig. 1 Flow diagram. Chart disposition at week 12 (primary endpoint), week 24 and Final Visit. The Completers population included all individuals
that had weight data within the specified visit window. Final Visit represents an individual’s last visit to the MWCC while following the 4 & 2 & 1
Plan. The time of the Final Visit varies by individual, depending on when they discontinued the 4 & 2 & 1 Plan
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Subgroup analysis of body weight and composition by
gender and senior status
Weight loss was first examined by gender. The mean
baseline body weight of females (102.2 ± 21.1 kg, n = 177)
was lower (p < 0.0001) than males (118.5 ± 19.1 kg, n =
132). Both males and females had significant reductions
(within group p ≤ 0.001) in body weight through 24 weeks.
Bivariate t-tests revealed that men had significantly greater
reductions in absolute (p ≤ 0.001, Additional file 5) and
percent (p < 0.05, Fig. 5a) body weight compared to
women at all times. This finding was confirmed by a ran-
dom effects regression model, controlling for baseline
weight and time, which showed a main effect of gender:
males lost on average 1.4 kg more than females through
the first 12 weeks (p < 0.0001). Body composition was also
examined by gender. Both males and females had con-
siderable reductions from baseline in body fat mass
(-36.8 % for males and −26.4 % for females) and smaller
reductions (up to approximately 5 % of baseline) in lean
body mass (p < 0.01 for within group analyses at all
times, Fig. 5b). Bivariate analyses revealed that males
lost a significantly higher percentage of their baseline
fat mass (p < 0.05), but not significantly more of their
baseline lean mass, than females. Similarly, in absolute
terms, with the exception of weeks 16 and 24, males lost
significantly more fat mass, and other than week 12, not
more lean mass than females (Additional file 5).
Since this plan is often used by seniors (age ≥65 years),
weight loss was further examined by age. The mean base-
line body weight for non-seniors (<65 years, n = 221,
113.7 ± 21.3 kg) was higher (p < 0.0001) than for seniors
(97.5 ± 18.5 kg, n = 88). Both seniors and non-seniors had
significant reductions in body weight throughout 24 weeks
and at Final Visit (p < 0.0001 compared to baseline). Bi-
variate t-tests showed although non-seniors lost more ab-
solute weight than seniors (p < 0.05 through 20 weeks,
Additional file 6), no differences in the percentage of
weight lost between the age groups was observed, except
at 2 weeks (p = 0.039, Fig. 6a). In a random effects regres-
sion model, controlling for baseline weight and time, there
was not a main effect of age (i.e., seniors vs. non-seniors)
on weight lost at 12 weeks; however, when also controlling
for gender, the relationship between senior status and
weight change became statistically significant. We then
examined for and found a significant interaction between
gender and senior status (p < 0.05). The rate of body
weight change through the primary time point of 12 weeks
was therefore examined for each gender/senior subgroup:
non-senior males had the highest rate of weight loss
(−1.06 kg/week; −1.15,−1.06 95 % CI), followed by senior
males (−0.89 kg/week; −0.94,−0.84), non-senior females
(−0.72 kg/week; −0.75,−0.69) and finally senior females
(−0.59 kg/week; −0.62,−0.56); all groups had significant
rates of weight loss (p < 0.0001).
Body composition was also examined by age group. Both
seniors and non-seniors had large, significant (p < 0.01)
within group reductions in body fat mass at each time
point, peaking at over 30 % loss of fat mass at 24 weeks.
Lean body mass also declined (p < 0.05) within each group
at each time point, but to a much lesser extent than did fat
mass (peak loss of approximately 5 % from baseline at
24 weeks). Percent changes from baseline in both lean and
fat mass were similar between groups, with only small,
sporadic differences noted (Fig. 6b).
Cardiometabolic risk factors
Based on measured baseline blood pressure (n = 198),
38 % were prehypertensive (systolic of 120–139 mmHg
and/or diastolic of 80–89 mmHg) and 48 % were hyper-
tensive (systolic ≥140 mmHg and/or diastolic ≥90 mmHg).
A reduction in both systolic and diastolic blood pressure
and heart rate occurred early in weight loss, with the
majority of the response occurring within the first
4 weeks (Table 2). Average reductions in blood pressure
were 11.3 ± 16.7 mm Hg and 6.6 ± 12.6 mm Hg for
systolic and diastolic blood pressure, respectively, at
Table 1 Baseline demographics
Demographic characteristic Mean ± SD or n (%)
N 310
Gender
Female 177 (57.1 %)
Male 133 (42.9 %)
Age (yrs) 53.5 ± 14.7
Seniors (age≥ 65 years) 88 (28.4 %)
Weighta (kg) 109.1 ± 21.7
BMIb (kg/m2) 37.7 ± 6.8
BMI categoryb
Overweight (BMI≥ 25 & <30 kg/m2) 32 (10.4 %)
Class I obesity (BMI≥ 30 & <35 kg/m2) 87 (28.3 %)
Class II obesity (BMI≥ 35 & <40 kg/m2) 78 (25.4 %)
Class III obesity (BMI≥ 40 kg/m2) 110 (35.8 %)
Lean body massc (kg) 61.8 ± 14.2
Body fat massc (kg) 47.0 ± 13.9
Current smoker 19 (6.1 %)
Co-morbid conditions
Diabetes//high blood sugar 65 (21.0 %)
High blood pressure 130 (41.9 %)
Arthritisd 57 (23.7 %)
Heart disease or past heart attack 14 (4.5 %)
Kidney disease 10 (3.2 %)
Liver disease 4 (1.3 %)
Abbreviations: BMI Body Mass Index
an = 309; bn = 307; cn = 286; dn = 241
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Fig. 3 Proportion of individuals with at least 5 % and at least 10 % reduction in baseline body weight. Analysis of the Completers population
which included all individuals with weight data at the given visit; sample sizes are designated below the graph. Final Visit represents an
individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan
Fig. 2 Percent change from baseline body weight. Mean (±SD) for the Completers population which included all individuals with weight data at
the given visit; sample sizes are designated below the graph. Intention-to-Treat Last Observation Carried Forward (ITT LOCF) values are also shown
for 12 and 24-week visits. Final Visit represents an individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan. Absolute weight changes in kg
are shown below the graph. Within group changes from baseline body weight using Wilcoxon signed-rank tests are shown: * p < 0.0001
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12 weeks (p < 0.0001). Improvements in blood pressure
were reflected in favorable shifts in individual blood
pressure categories (from hypertensive to prehyperten-
sive or from prehypertensive to normal) in 47, 49 and
42 % of the individuals on this plan at 4, 12 and
24 weeks, respectively. Heart rates decreased, on aver-
age, by 3.0 and 3.7 beats per minute at 12 and 24 weeks,
respectively (p < 0.05). Waist and hip circumferences
were reduced (p < 0.0001) at all times throughout the
study (Table 2), with significant corresponding improve-
ments in waist-to-hip ratio through 12 weeks (p < 0.01).
BMI declined (p < 0.0001) at all time points.
Program adherence
The average number of meal replacements consumed on
the 4 & 2 & 1 Plan based on self-report, was ≥ 3.4 of the
4 assigned per day, corresponding to >85 % adherence
through 24 weeks. The adherent group (see definition in
methods; n = 259) lost more weight during weeks 8
through 24 and at Final Visit compared to the non-
adherent group (n = 50, p < 0.05). When meal replacement
adherence was considered only through week 12, the
adherent group (n = 260) had greater weight loss at
8 weeks, 12 weeks, and Final Visit (p < 0.05), than the
non-adherent group (n = 49). Adherence to weekly visits
was also examined: on average, clients attended 85 % of
their weekly counseling sessions while on the program.
When examined with bivariate analyses comparing adher-
ent and non-adherent groups, no relationship was found
between attendance at weekly MWCC counseling sessions
and weight loss on this plan.
Other program information
Individuals on the 4 & 2 & 1 Plan were prescribed an
average of 26.2 weeks of weight loss, and stayed on the
4 & 2 & 1 Plan for an average of 17.4 weeks. Twenty
one percent (65/310) who started active weight loss on
the 4 & 2 & 1 Plan subsequently changed to another
Medifast weight loss meal plan(s) and spent an average
of 16.0 additional weeks in active weight loss. During
this time, they lost, on average, an additional 2.6 kg or
2.7 % of baseline body weight, for a total loss of
approximately 12 kg over the entire weight loss period
(4 & 2 & 1 and all other Medifast weight loss plans).
Following the Weight Loss phase, 43 of 310 (14 %)
individuals on the 4 & 2 & 1 Plan entered the Transi-
tion phase for an average of just under 4 weeks during
which individuals continued to lose approximately
0.5 kg, <1 % of baseline body weight (p = 0.020). Sixty-
two of 310 (20 %) individuals entered the Maintenance
Fig. 4 Change from baseline body weight, lean body mass and body fat mass. Mean (±SD) for the Completers population which included all
individuals with weight data at the given visit; sample sizes are designated below the graph. Within group changes from baseline using Wilcoxon
signed-rank tests are shown: * p < 0.0001
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phase for an average of 34 weeks during which individ-
uals regained, on average, 1.6 kg (p < 0.0001, 1.9 % of
weight at start of this phase). Despite this regain, the weight
of these individuals remained 16.8 ± 10.2 kg (15–16 %)
below their baseline body weight (p < 0.0001). Those indi-
viduals who started the Maintenance Phase had lost, on
average, significantly (p < 0.0001) more weight (−16.2 ±
8.6 kg) specifically while on the 4 & 2 & 1 Plan compared
to those who never started the Maintenance phase (−9.2 ±
7.8 kg, n = 244).
Safety
Signs, symptoms and incidents notated in the charts
represented lay accounts, and their descriptions were
typically quite general in nature; relatedness and severity
often could not be assessed from the information pro-
vided. Focusing on those that occurred at frequencies of
>5 %, signs and symptoms were primarily gastrointes-
tinal disturbances (10.6 % constipation, 7.1 % abdominal
gas/bloating) or general complaints of hunger (18.1 %),
fatigue (11.0 %), and stress/anxiety (5.2 %), or generally
Fig. 5 Percent change from baseline in (a) body weight and (b) lean and fat mass by gender. Mean (±SD) for the Completers population which
included all individuals with weight data at the given visit; sample sizes are designated below the graph. Final Visit represents an individual’s last
visit to the MWCC while on the 4 & 2 & 1 Plan. Significance levels for all within group changes from baseline were p < 0.0001 for body weight
and fat mass and p < 0.01 lean mass (not shown). Significance levels for between group comparisons using bivariate t-tests at each time point are
shown: *p < 0.05; **p < 0.01; ***p < 0.0001
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feeling sick (22.3 %) at some time during the period of
study. This latter term was too general to categorize or
assess further. High blood pressure (not necessarily
worsening) was noted in 6.5 % of charts; a majority of
these reports occurred in individuals who had pre-
existing hypertension. There were 9 reports (2.9 %) of
serious events, including stroke, heart attack, two chole-
cystectomies, and hospitalizations associated with a
blood clot, ruptured hemorrhoid, high fever, and for two
unspecified reasons. The ruptured hemorrhoid was sec-
ondary to constipation. Four of 310 clients (1.3 %)
reported gall bladder pain/stones, including the two
noted above which required surgery.
Discussion
The use of portion-controlled meal replacements as a
part of a structured meal plan has been shown to be a
safe and effective method for increasing dietary compli-
ance and providing clinically meaningful, sustainable
weight loss and improvements in weight-related disease
risk factors [14, 16, 17, 21–23]. This retrospective chart
review study sought to characterize the effectiveness of
Fig. 6 Percent change from baseline (a) body weight and (b) lean and fat mass by age group. Mean (±SD) for the Completers population
grouped by age (<65 and ≥65 years). Completers included all individuals with weight data at the given visit; sample sizes are designated below
the graph. Final Visit represents an individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan. Significance levels for all within group changes
from baseline were p < 0.0001 for body weight, p≤ 0.002 for fat mass and p ≤ 0.05 for lean mass (not shown). Significance levels for between
group comparisons using bivariate t-tests at each time point are shown: *p < 0.05; **p < 0.01; ***p < 0.0001
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the Medifast 4 & 2 & 1 Plan using a systematic approach
in a broad sample of real world customers who used the
plan in the setting of an MWCC. MWCC weight loss
programs include weekly visits with behavioral counsel-
ing. This study demonstrated the program was effective
for producing steady, significant weight loss over 24 weeks
across a broad population of adults who were overweight
or obese. At the primary endpoint of 12 weeks, mean
weight loss from baseline among completers of −10.9 kg
(-10.1 %) compares favorably with results from a meta-
analysis of low calorie (>800 to ≤1600 kcal/day) meal
replacement studies, in which the average pooled weight
loss of completers at 3 months ranged between 6.19 and
6.50 kg (approximately 7 % from baseline) [14]. Differ-
ences between these results, however, may be due to dif-
ferences in the study populations and/or the wider calorie
range of the studies included in the meta-analysis. Regard-
less, half of those on the 4 & 2 & 1 Plan had clinically
meaningful weight loss of 5 % or more from baseline start-
ing as early as 4 weeks, 85 % had lost ≥5 % by the 12-week
primary endpoint. Nearly all individuals (96 %) who stayed
on the 4 & 2 & 1 Plan for 24 weeks had lost at least 5 %
and three quarters had lost at least 10 % of their baseline
body weight, thus meeting guidance goals [1]. In this
study, Final Visit (clients’ last weekly visit while following
the 4 & 2 & 1 Plan) represents a more stringent assess-
ment of the effectiveness of the plan because it takes into
consideration attrition that took place before 24 weeks.
This analysis found that approximately 70 % had lost ≥5 %
of their baseline body weight while on the program, irre-
spective of how long they stayed on the plan. This latter
finding was similar to the ITT LOCF results.
Most weight loss studies have focused primarily on
women [6], and relatively few studies include adults over
the age of 65 years [7]. The population in this study
reflected the demographics of customers who used the 4
& 2 & 1 Plan at MWCCs, and included 43 % men and
28 % seniors age ≥65 years. Subgroup analyses showed
both men and women, and seniors and non-seniors had
significant weight loss through 24 weeks and at Final
Visit. Similar to other studies, after controlling for
baseline weight, men lost more weight than women in
both age categories [24]. One explanation may be the
set calorie level provided by the plan, which would gen-
erally represent a greater caloric deficit for men who, as
a group, weighed more than women at baseline. How-
ever, other physiological and/or behavioral factors
known to contribute to differences in weight loss be-
tween the genders may also have factored into this dif-
ferential response [24, 25].
Across the entire study population, weight loss on the
4 & 2 & 1 Plan was primarily a result of reductions in
body fat mass (≥80 % of the weight lost was from fat
starting from 12 weeks onward), accompanied by much
smaller losses in lean mass, the latter of which occurred
early in the weight loss phase and then stabilized. Al-
though some loss of lean mass is always expected during
weight loss [26], minimizing lean mass loss is an import-
ant health and safety consideration in order to maintain
strength and physical function and also to maximize
basal metabolic rate for long term weight maintenance.
At 4 weeks, approximately 33 % of the total weight
change was due to loss of lean mass, whereas at later
time points, lean mass represented considerably smaller
proportions (<20 %) of the total weight lost. Although
the changes in the proportion of lean to total body
weight during energy deficit can vary considerably de-
pending on many factors (e.g., protein intake, activity
type and level, stage of weight loss, gender, BMI, age),
cross-sectional estimates of these proportions typically
range from 36 to 40 % for men and from 31 to 33 % for
women [26–29]. This program fared well against these
estimates. While increases in activity were encouraged,
the program did not include a structured exercise regi-
men; therefore, the nutritional composition of this meal
plan is likely an important contributing factor in the re-
tention of lean mass. Recent research suggests protein
intake in the range of at least 1.1 to 1.6 g/kg body weight
Table 2 Cardiometabolic risk factors
Mean (SD)
4 weeks 12 weeks 24 weeks Final visit
n Baseline Change n Baseline Change n Baseline Change n Baseline Change
BMI (kg/m2) 287 37.5 (6.3) −1.9*** (0.9) 185 37.0 (6.2) −3.7*** (1.7) 81 38.2 (6.0) −5.5*** (2.6) 304 37.6 (6.8) −3.6*** (2.8)
SBP (mmHg) 175 130.5 (16.1) −9.9*** (16.9) 114 129.5 (15.9) −11.3*** (16.7) 52 130.2 (16.9) −7.8** (19.4) 162 131.3 (16.5) −9.5*** (15.6)
DBP (mmHg) 175 86.7 (11.1) −5.9*** (12.1) 114 86.1 (10.4) −6.6*** (12.6) 52 85.8 (11.9) −3.9* (14.2) 163 86.7 (11.4) −5.6*** (11.6)
Pulse (BPM) 175 73.4 (12.0) −2.9*** (10.1) 111 72.7 (11.2) −3.0*** (10.5) 51 74.2 (11.3) −3.7* (9.3) 161 74.2 (12.2) −2.3** (11.6)
WC (cm) 158 112.9 (14.8) −5.0*** (3.5) 73 111.0 (14.1) −9.8*** (5.9) 24 114.9 (16.7) −13.6*** (7.3)
HC (cm) 158 124.8 (13.6) −4.0*** (3.5) 73 123.5 (13.6) −8.7*** (5.6) 24 125.2 (12.7) −12.5*** (6.8)
WHR 158 0.91 (0.10) −0.01*** (0.04) 73 0.90 (0.09) −0.02** (0.05) 24 0.92 (0.11) −0.02 (0.05)
Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, BPM Beats Per Minute, WC Waist Circumference, HC Hip
Circumference, WHR Waist-to-Hip Ratio. Within group changes from baseline using Wilcoxon signed-rank tests: * p < 0.05; ** p < 0.01; *** p < 0.0001
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is optimal for retention of lean mass during weight loss
[30–32]. The 4 & 2 & 1 Plan provides approximately
120–160 g/day of high quality protein which roughly
translated into approximately 1.1 to 1.5 g protein/kg
body weight (assuming mean baseline weight of 109.1 kg)
in this study population.
Conservation of lean mass is a particularly important
safety consideration in seniors due to naturally-occurring
sarcopenia and concerns over loss of muscle mass and
possible concomitant loss in physical function [7]. For this
reason, body composition between seniors and non-
seniors was compared. To account for the fact that the
non-seniors group weighed more at baseline, lean and fat
masses were examined as a percentage of their respective
baseline values. This analysis showed seniors and non-
seniors had nearly identical changes in lean and fat mass.
Both groups lost more than 30 % of their baseline fat
mass, and neither group lost more than 5 % of their initial
lean mass on the program. Thus seniors and non-
seniors alike had a strong tendency to conserve lean
body mass while losing fat mass on the 4 & 2 & 1
Plan. Indeed, a recent 12-week pilot study in older adults
who used four Medifast Meal Replacements daily reported
7.8 kg reduction in body weight (comprised of 5.3 kg fat
mass and 2.5 kg lean mass) with no loss in physical
function [33].
Body composition was also examined by gender as
previous reports have suggested that changes in body
composition during energy deficit may be gender spe-
cific [27, 34]. Males lost significantly more fat mass (ab-
solute and as a proportion of baseline fat mass) but
similar absolute and proportional lean mass compared
to females. Thus it is reasonable to conclude that the
larger weight loss experienced by males was due pri-
marily to greater losses of fat mass, and that the 4 & 2
& 1 Plan was equally efficient at preserving lean mass
in both genders.
An important medical goal of intentional weight loss
is to reduce cardiovascular risk factors. Reductions in
BMI, blood pressure (systolic and diastolic), heart rate,
and central adiposity all accompanied weight loss on the
4 & 2 & 1 Plan. The reduction in both systolic and dia-
stolic blood pressure and heart rate occurred early in
weight loss, with the majority of the response occurring
within the first 4 weeks. During this time, individuals
lost an average of 5 % of baseline body weight, reinfor-
cing the tenet that even modest reductions in weight
lead to clinically meaningful health benefits. The magni-
tude of the blood pressure reductions observed in this
study (10–11 mm Hg systolic and 4–6 mm Hg diastolic)
is associated with a substantial reduction in cardiovascu-
lar disease risk [35].
Adherence is generally a key factor in weight loss suc-
cess [36, 37]. Results from previous studies have shown
that the use of highly structured meal plans [38, 39],
consumption of portion-controlled meal replacements
[14, 21, 23, 36], and support session attendance [16, 36, 37]
may promote greater adherence and are all positively asso-
ciated with improved weight loss outcomes. In this study,
program adherence was assessed based on self-reported
consumption of meal replacements and by attendance at
weekly visits. Both of these program adherence compo-
nents were high (>85 %) while individuals were on the pro-
gram. Adherence to meal replacement consumption was
positively related to weight loss, whereas an association
with visit attendance was not detected in this study. In a
previous chart review of clients following the Medifast 5 &
1 Plan at MWCCs, adherence (both meal replacement and
attendance) was approximately 70 %, and both factors were
positively related to weight loss [16]. Despite differences in
data collection and analysis methods, meal replacement ad-
herence was significantly associated with weight loss in
both studies, reinforcing the importance of this factor to
weight loss success on these programs. The higher overall
rate of attendance adherence in the current study may have
made an association more difficult to detect than in the
previous study.
A limitation of the study was that data for the primary
endpoint, change in body weight at 12 weeks, was only
available for approximately 60 % of the study sample.
Given the retrospective nature of this study, data missing
at a specified time point may not be a true measure of
attrition per se, as factors such as completion of pre-
scribed program length, no visit/data within the window
of that specific time point, and changing to another
weight loss meal plan might not be considered attrition
in a traditional sense. This may be an important consid-
eration given that more than 20 % of charts indicate the
reason for a client’s Final Visit on the 4 & 2 & 1 Plan
was to switch meal plans and continue their weight loss
on another Medifast plan(s). Nonetheless, retention of
approximately 60 % at 12 weeks is generally lower than
that the rates previously reported in a meta-analysis of
randomized, controlled weight loss trials, but higher
than other commercial programs where reported reten-
tion at 10 weeks and 3 months was 50 and 42 %, re-
spectively [40, 41]. To address the concern of missing
data, data for the primary outcome were analyzed by
three different methods (completers, ITT LOCF and
mixed model regression analyses); all methods provided
consistent results. Another observation in this study was
the relatively large variability in responses. This is similar
to other retrospective weight loss studies [16, 40] and
likely reflects the fact that the study included real cus-
tomers who were not following a defined study protocol.
Moreover, the study population came from over 20 cen-
ters and was highly heterogeneous as a result of the
broad entrance criteria. These latter points support the
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generalizability of the study results among MWCC cli-
ents and provide a true picture of customer experience
on this program. Nonetheless, this study was retrospect-
ive in nature, and as such, was neither randomized nor
controlled. Evaluation of the 4 & 2 & 1 Plan in a pro-
spective, randomized, controlled study would provide a
broader assessment of efficacy.
The retrospective nature of this study limits any weight
data available after use of the 4 & 2 & 1 Plan to those who
subsequently followed another Medifast plan. Accordingly,
weight maintenance data in this study are limited to the
relatively small proportion of individuals (20 %, n = 62)
who entered a formal Maintenance phase; however, the
available data indicated minimal weight regain (average
of <2 kg, <2 %) during an average follow-up period of
34 weeks. The total follow-up period for this group, in-
cluding the Weight Loss, Transition (as applicable) and
Maintenance phases, was over a year, with overall sus-
tained weight loss of 17 kg. Weight at the end of the
Maintenance phase remained 15–16 % below the
group’s baseline weight, suggesting the program was ef-
fective for weight maintenance for those who entered
this phase.
All recorded medical events were collected and analyzed
in a systematic fashion. An evaluation of these events was
consistent with previously reported side effects [16], pri-
marily gastrointestinal disturbances, and general complaints
of hunger, fatigue, and stress which are also often associated
with intentional weight loss. Both obesity and weight loss
are known to be significant risk factors for the development
of gallstones [42, 43]. Just over 1 % of individuals reported
gallbladder pain/stones, some requiring surgery. This rate is
considerably lower than the 10–36 % rate of gallstones
reported among obese subjects who lose weight rapidly
[43–46], perhaps reflecting a more moderate rate of weight
loss and adequate fat provided by the meal plan. In contrast
to most prospective weight loss studies that limit the study
population to obese but generally healthy individuals, this
study population had very broad inclusion criteria and in-
cluded many individuals with baseline health issues, some
serious (e.g., diabetes, kidney, liver and heart disease). Given
the high prevalence of pre-existing health issues and the
relatively long study period (6 months), the number of ser-
ious medical issues reported was relatively low. Indeed, the
observed rate of serious events is similar to placebo rates
observed in pharmacotherapy trials with similar popula-
tions [47–49]. Although the safety data were limited by the
retrospective nature of the study, based on the available
data, the 4 & 2 & 1 Plan appeared to be generally well toler-
ated in this broad range of people with various health
issues, and may have possible lower than expected rates of
gallbladder issues.
This study reinforces previous findings that weight loss
programs incorporating meal replacements can be an
effective approach to weight loss and weight mainten-
ance [14, 21]. Another Medifast meal replacement plan,
the 5 & 1 Plan, has also been shown to be effective for
weight loss in both retrospective studies and controlled
trials [16–18].
Conclusions
The Medifast 4 & 2 & 1 Plan used in a structured, sup-
portive environment of a commercial weight control
center was effective over a 6-month period for achieving
clinically meaningful weight loss and preserving lean
body mass in a broad population of overweight and
obese adults. Among the subset of those who entered
the Maintenance phase, the Medifast Maintenance Plan
was also effective for maintaining weight loss to within
2 % of the start of this phase. Overall, the Medifast pro-
gram appeared to be well tolerated. While randomized
clinical trials are needed to broaden these study results,
this retrospective analysis demonstrates that when used
in the setting of an MWCC, the 4 & 2 & 1 Plan meets
medical goals for weight loss with concomitant improve-
ments in cardiovascular risk markers. Thus, the 4 & 2 &
1 Plan would be an appropriate commercial choice for in-
dividuals or as an option for clinician referrals.
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